Uvax Bio Announces Interim Results from a Phase 1 Clinical Trial Evaluating its HIV-1 Vaccine [Yahoo! Finance]
Dynavax Technologies Corporation (DVAX)
Last dynavax technologies corporation earnings: 3/11 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.dynavax.com
Company Research
Source: Yahoo! Finance
The trial also demonstrated robust immune responses, with 100% of subjects showing antibody responses after two priming doses. The vaccine uses Uvax Bio's proprietary 1c-SApNP platform technology to generate virus-like particles that closely resemble the target virus. The company expects to report topline data from a second interim analysis in the first quarter of 2025. The UVAX-1107 protein nanoparticle vaccine was safe and well-tolerated in healthy volunteers at the planned Interim Analysis #1 The planned Interim Analysis #1 was performed after two priming doses of UVAX-1107, out of the planned two priming vaccinations with UVAX-1107 followed by two booster vaccinations with UVAX-1107/UVAX-1197 A planned immunogenicity analysis showed robust vaccine-matched IgG antibody responses in 100% of subjects after receiving two priming doses of UVAX-1107 NEWARK, Del., November 19, 2024 BUSINESS WIRE Uvax Bio, LLC , ("Uvax" or "the Company") a privately held, clinical-stage vaccine co
Show less
Read more
Impact Snapshot
Event Time:
DVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DVAX alerts
High impacting Dynavax Technologies Corporation news events
Weekly update
A roundup of the hottest topics
DVAX
News
- Dynavax Technologies Corporation (DVAX): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]Yahoo! Finance
- Dynavax Announces $100 Million Accelerated Share Repurchase ProgramPR Newswire
- Dynavax Technologies Corporation Just Recorded A 9.1% EPS Beat: Here's What Analysts Are Forecasting Next [Yahoo! Finance]Yahoo! Finance
- Dynavax Technologies Corp (DVAX) Q3 2024 Earnings Call Highlights: Record Hep B Sales and ... [Yahoo! Finance]Yahoo! Finance
- Dynavax Technologies Co. (NASDAQ: DVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.MarketBeat
DVAX
Earnings
- 11/7/24 - Beat
DVAX
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/12/24 - Form 8-K
- DVAX's page on the SEC website